Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland
Open Access
- 7 August 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2121-2134
Abstract
1. Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies including cancers of the oral cavity, oropharynx, hypopharynx, and larynx.1 Worldwide, HNSCC is the seventh most common c...Keywords
Funding Information
- MSD, Bürgenstrasse
This publication has 32 references indexed in Scilit:
- PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesCancer Treatment Reviews, 2026
- Comparing Survival Outcomes and Recurrence Patterns in Oral Cavity Squamous Cell Carcinoma (OCSCC) Patients Treated With Curative Intent Either With Adjuvant or Definitive (Chemo)radiotherapyClinical Oncology, 2025
- Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in SwitzerlandPharmacoEconomics - Open, 2023
- A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinomaCancer Medicine, 2023
- An EQ-5D-5L Value Set for BelgiumPharmacoEconomics - Open, 2022
- Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in SwitzerlandThe European Journal of Health Economics, 2021
- Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancerHead & Neck, 2021
- Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation TechniquesJAMA Oncology, 2017
- A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 TestingJournal of Thoracic Oncology, 2016